ABSTRACT
Introduction One of the drawbacks of fetoscopic endoluminal tracheal occlusion (FETO) for congenital diaphragmatic hernia is the need for a second invasive intervention to reestablish airway patency. The “Smart-TO” (Strasbourg University-BSMTI, France) is a new balloon for FETO, which spontaneously deflates when positioned near a strong magnetic field, e.g., generated by a magnetic resonance image (MRI) scanner. Translational experiments have demonstrated its efficacy and safety. We will now use the Smart-TO balloon for the first time in humans. Our main objective is the efficacy of prenatal deflation of the balloon by the magnetic field generated by an MRI scanner.
Material and methods This is a phase-I study conducted in the fetal medicine units of Antoine–Béclère Hospital, France, and UZ Leuven, Belgium. Conceived in parallel, protocols were amended by the local Ethics Committees, resulting in some minor differences. This trial is a single-arm interventional feasibility study. Twenty (France) and 25 (Belgium) participants will have FETO with the Smart-TO balloon. Balloon deflation will be scheduled at 34 weeks or earlier if clinically required. The primary endpoint is the successful deflation of the Smart-TO balloon after exposure to the magnetic field of an MRI, assessed through ultrasound immediately after MRI-exposure. The secondary objective is to report on the safety of the balloon. The percentage of fetuses in whom the balloon is deflated after exposure will be calculated with its 95% confidence interval. Safety will be evaluated by reporting the nature, number, and percentage of serious unexpected or adverse reactions.
Conclusion This phase-I study may provide the first evidence of the potential to reverse the occlusion by Smart-TO and free the airways non-invasively, as well a safety data.
Competing Interest Statement
Nicolas Sananès is the primary co-inventor of the Smart-TO balloon. None of the authors has any financial interest in BS?Medical Tech Industry, manufacturing the balloon. There are no other conflicts of interest.
Clinical Trial
NCT04931212 and NCT05100693
Clinical Protocols
https://clinicaltrials.gov/ct2/show/NCT04931212
https://clinicaltrials.gov/ct2/show/NCT05100693
Funding Statement
DB is funded by the Erasmus + Programme of the European Union (Framework Agreement number: 2013-0040). This publication reflects the views only of the authors, and the Commission cannot be held responsible for any use which may be made of the information contained therein. JD is funded by the Great Ormond Street Hospital Charity Fund. In Paris, the present clinical protocol is funded by a grant from Assistance Publique – Hôpitaux de Paris (CRC19). In Leuven, the study is funded by the Klinisch Onderzoeks- en Ontwikkelingsfonds of the UZ Leuven (S65423). The funders had and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
In France, approval was provided by the committee for the protection of persons concerned (CPP “Ile de France VIII”) in January 2021 (# 21 01 01), and the French medicines controls authorities (ANSM) in March (2020-A02834-35-A). In Belgium, approval was given by the Ethics Committee on Clinical Studies of the University Hospitals Leuven in July 2021 (S65423). The study was registered at the Federal Agency for Medicines and Health Products (FAGG/80M0892).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* shared first and last authorship.
Disclosure statement: Nicolas Sananès is the primary co-inventor of the Smart-TO balloon. None of the authors has any financial interest in BS-Medical Tech Industry, manufacturing the balloon. There are no other conflicts of interest.
Funding: DB is funded by the Erasmus + Programme of the European Union (Framework Agreement number: 2013-0040). This publication reflects the views only of the authors, and the Commission cannot be held responsible for any use which may be made of the information contained therein. JD is funded by the Great Ormond Street Hospital Charity Fund. In Paris, the present clinical protocol is funded by a grant from Assistance Publique – Hôpitaux de Paris (CRC19). In Leuven, the study is funded by the Klinisch Onderzoeks- en Ontwikkelingsfonds of the UZ Leuven (S65423).
Data Availability
No datasets were generated or analysed during the current study. All relevant data from this study will be made available upon study completion.
